TGFB1 and diabetic kidney disease: A number of potential anti-fibrotic drugs have been identified in preclinical studies, including neutralizing antibodies against TGF-β1 and connective tissue growth factor and a small molecule inhibitor of apoptosis signal-regulating kinase 1; however, their effects on diabetic nephropathy have been limited [29,30,31].